Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Tuesday, down -3.23% from the previous trading day, before settling in for the closing price of $1.24. Over the past 52 weeks, FATE has traded in a range of $0.66-$5.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 5.00% over the last five years. While this was happening, its average annual earnings per share was recorded 21.19%. With a float of $107.09 million, this company’s outstanding shares have now reached $114.60 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is -159.5%, operating margin of -1503.47%, and the pretax margin is -1318.93%.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 6.58%, while institutional ownership is 84.23%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.42% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.25 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 2.33 million was better than the volume posted last year of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 4.18%. Additionally, its Average True Range was 0.15.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 46.50%, which indicates a significant increase from 1.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.74% in the past 14 days, which was higher than the 116.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1995, while its 200-day Moving Average is $1.8928. Now, the first resistance to watch is $1.2767. This is followed by the second major resistance level at $1.3533. The third major resistance level sits at $1.3967. If the price goes on to break the first support level at $1.1567, it is likely to go to the next support level at $1.1133. Now, if the price goes above the second support level, the third support stands at $1.0367.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 137.56 million has total of 114,604K Shares Outstanding. Its annual sales at the moment are 13,630 K in contrast with the sum of -186,260 K annual income. Company’s last quarter sales were recorded 1,630 K and last quarter income was -37,620 K.
